Upstream Bio

Upstream Bio

  • Founded: 2021
  • Location: Waltham, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1b
  • Therapy area: Asthma
  • Drug types: LNG
  • Lead product: UPB-101
  • Product link:
  • Funding: $200M B Jun 2023; $200M A Jun 2022
  • Investors: OrbiMed, Access Biotechnology, Decheng Capital, Altshuler Shaham Provident Funds Ltd., TCG X, HBM Healthcare Investments, Omega Funds, Samsara BioCapital

job board

Short description:

Therapies for allergic, inflammatory conditions

Drug notes:

Contact us to add description:

Long description:

Upstream Bio is dedicated to leveraging advanced scientific techniques in cellular and molecular biology to address inflammatory and allergic diseases. Their mission focuses on developing innovative therapies that target specific biological pathways implicated in these conditions rather than targeting and treating disease by symptoms. Focus on these upstream targets could allow a therapeutic to benefit several inflammatory diseases, rather than treating a single disease. Bio aims to accelerate the discovery and development of treatments that improve patient outcomes and quality of life. They position themselves as a crucial partner in biotechnology, committed to advancing research and translating scientific insights into effective therapies for inflammatory diseases.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy